10-Q: Monopar Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Monopar Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its Wilson disease and radiopharmaceutical programs.

Summary

• Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Wilson disease and novel radiopharmaceuticals for oncology.
• The company's lead Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine.
• Monopar's radiopharmaceutical programs include Phase 1-stage MNPR-101-Zr for imaging advanced cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of advanced cancers, that express urokinase plasminogen activator receptor (uPAR).
• As of March 31, 2025, Monopar had cash, cash equivalents, and investments totaling $54.6 million.
• Management estimates that the available cash will be sufficient to fund operations at least through December 31, 2026.
• The company incurred an accumulated deficit of approximately $78.4 million as of March 31, 2025, and has not generated any revenue since inception.
• Research and development expenses for the three months ended March 31, 2025, were $1.64 million, compared to $0.97 million for the same period in 2024.
• General and administrative expenses for the three months ended March 31, 2025, were $1.58 million, compared to $0.76 million for the same period in 2024.
• Net loss for the three months ended March 31, 2025, was $2.63 million, or $0.38 per share, compared to a net loss of $1.64 million, or $0.51 per share, for the same period in 2024.
• The company is preparing to submit an NDA to the FDA for ALXN1840 in early 2026.
• Monopar is actively exploring opportunities to expand its radiopharmaceutical pipeline through internal development efforts.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company has a solid cash position and is advancing its clinical programs, it is also incurring increasing losses and faces significant risks and uncertainties. The outlook is cautiously optimistic, but dependent on successful execution and future financing.

Positives

• Monopar has a strong cash position of $54.6 million, which is expected to fund operations through December 31, 2026.
• The company is advancing its lead Wilson disease candidate, ALXN1840, towards NDA submission in early 2026.
• Monopar has two radiopharmaceutical programs in Phase 1 clinical trials: MNPR-101-Zr and MNPR-101-Lu.
• The company is actively working to expand its radiopharmaceutical pipeline through internal development efforts.
• Monopar presented data on the long-term efficacy and safety of ALXN1840 at the European Association for the Study of the Liver (EASL) International Liver Congress 2025.

Negatives

• Monopar has an accumulated deficit of $78.4 million and has not generated any revenue since inception.
• The company expects to continue incurring losses for the foreseeable future.
• Research and development expenses increased to $1.64 million for the three months ended March 31, 2025.
• General and administrative expenses increased to $1.58 million for the three months ended March 31, 2025.
• Net loss increased to $2.63 million, or $0.38 per share, for the three months ended March 31, 2025.

Risks

• The company's ability to fund future operations is dependent on obtaining additional funding and/or executing collaborative research agreements.
• There is no certainty that future financing or collaborative research agreements will occur in the amounts required or at a time needed to maintain operations.
• The company's ability to generate revenue and achieve profitability will depend on successfully completing the development of its product candidates and obtaining necessary regulatory approvals.
• The company faces significant competition from other radiopharmaceutical, biotechnology, and pharmaceutical companies.
• The company relies on third parties to conduct manufacturing, non-clinical studies, and clinical trials.

Future Outlook

Monopar expects its current funds to be sufficient to fund planned operations at least through December 31, 2026, including assembling a regulatory package and filing an NDA for ALXN1840, continuing clinical trials for MNPR-101-Zr and MNPR-101-Lu, advancing MNPR-101-Ac into the clinic, and investing in internal R&D projects.

Management Comments

• Management estimates that currently available cash will provide sufficient funds to enable the Company to meet its obligations at least through December 31, 2026.

Industry Context

Monopar is operating in the competitive biopharmaceutical industry, focusing on rare diseases and oncology. The company's success depends on its ability to develop and commercialize innovative treatments, navigate regulatory hurdles, and compete with larger pharmaceutical companies.

Comparison to Industry Standards

• Monopar's focus on radiopharmaceuticals aligns with a growing trend in oncology, with companies like Novartis and Telix Pharmaceuticals actively developing and commercializing radioligand therapies.
• The development of ALXN1840 for Wilson disease addresses a rare disease with limited treatment options, similar to efforts by companies like Ultragenyx and BioMarin in other rare disease areas.
• The company's cash runway through December 2026 is a key factor for investors, as it provides a timeline for achieving key milestones and potential value creation.
• Monopar's increased R&D spending reflects the investment required to advance its clinical programs, consistent with industry norms for clinical-stage biopharmaceutical companies.

Related Party Transactions

• As of March 31, 2025, Tactic Pharma, LLC (Tactic Pharma), the Company's initial investor, beneficially owned 14% of Monopar's common stock, and during the three months ended March 31, 2025, there were no transactions between Tactic Pharma and Monopar.
• One of the Company's board members was also a Managing Member of Tactic Pharma as of March 31, 2025.
• Chandler D. Robinson is a Company Co-Founder, Chief Executive Officer, common stockholder, Managing Member of Tactic Pharma, former Manager of the predecessor LLC, Manager of CDR Pharma, LLC and Board member of Monopar as a C Corporation as of March 31, 2025.

Stakeholder Impact

• Shareholders: Dilution is possible through future equity offerings.
• Employees: Job security is dependent on the company's ability to secure funding and advance its programs.
• Patients: Potential for new treatments for Wilson disease and advanced cancers.
• Suppliers: Continued business relationships are dependent on the company's financial stability.

Next Steps

• Assemble a regulatory package and submit an NDA to the FDA for ALXN1840 in early 2026.
• Continue to conduct and conclude the first-in-human imaging and dosimetry clinical trial with MNPR-101-Zr.
• Continue to conduct the first-in-human therapeutic clinical trial of MNPR-101-Lu.
• Advance the preclinical MNPR-101-Ac program into the clinic.
• Invest in internal R&D projects to expand the radiopharmaceutical pipeline.

Key Dates

Keywords

Monopar Therapeutics, ALXN1840, Wilson disease, radiopharmaceuticals, MNPR-101, oncology, clinical trials, NDA, financial results, biopharmaceutical